相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Urinary metabolomics of HCV patients with severe liver fibrosis before and during the sustained virologic response achieved by direct acting antiviral treatment
Elisa Biliotti et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C
Velia Chiara Di Maio et al.
LIVER INTERNATIONAL (2021)
Hepatic Accumulation of Hypoxanthine: A Link Between Hyperuricemia and Nonalcoholic Fatty Liver Disease
Paola Toledo-Ibelles et al.
ARCHIVES OF MEDICAL RESEARCH (2021)
1H NMR-based metabolite profiling for biomarker identification
Ruan A. Silva et al.
CLINICA CHIMICA ACTA (2020)
Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study
Raffaella Lionetti et al.
ANNALS OF HEPATOLOGY (2019)
Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt
Aya A. Youssef et al.
JOURNAL OF CHROMATOGRAPHIC SCIENCE (2019)
Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure
Mei Lu et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
Poonam Mathur et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2018)
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
Paul Kwo et al.
GASTROENTEROLOGY (2017)
Safety and Efficacy of Current Direct-Acting Antiviral Regimens in Kidney and Liver Transplant Recipients With Hepatitis C: Results From the HCV-TARGET Study
Varun Saxena et al.
HEPATOLOGY (2017)
NMR-based pharmacometabonomics: A new paradigm for personalised or precision medicine
Jeremy R. Everett
PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY (2017)
Cathodic adsorptive stripping voltammetric determination of Ribavirin in pharmaceutical dosage form, urine and serum
Ahmed A. Abdel Gaber et al.
ARABIAN JOURNAL OF CHEMISTRY (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Prevention and management of treatment failure to new oral hepatitis C drugs
Laura Benitez-Gutierrez et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Pharmacogenetics of ribavirin-induced anemia in HCV patients
Antonio D'Avolio et al.
PHARMACOGENOMICS (2016)
Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators
Rahul Shubhra Mandal et al.
SCIENTIFIC REPORTS (2016)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton et al.
GASTROENTEROLOGY (2015)
Current race in the development of DAAs (direct-acting antivirals) against HCV
Erik De Clercq
BIOCHEMICAL PHARMACOLOGY (2014)
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations
Clara T. M. M. de Kanter et al.
CLINICAL PHARMACOKINETICS (2014)
Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir
Manel Aouri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 Induce Different Age-Related Metabolic Profiles Revealed by 1H-NMR Spectroscopy in Urine and Feces of Mice
Elisa Brasili et al.
JOURNAL OF NUTRITION (2013)
NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis
Ai-hua Zhang et al.
MAGNETIC RESONANCE IN CHEMISTRY (2013)
Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
Tatsuo Miyamura et al.
VIRUSES-BASEL (2012)
Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease
Emanuele Durante-Mangoni et al.
DIGESTIVE AND LIVER DISEASE (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction
Alexander J. Thompson et al.
GASTROENTEROLOGY (2010)
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
Jacques Fellay et al.
NATURE (2010)
The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus
NM Dixit et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Human plasma adenosine deaminase 2 is secreted by activated monocytes
S Iwaki-Egawa et al.
BIOLOGICAL CHEMISTRY (2006)
High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load
A Tsubota et al.
JOURNAL OF GASTROENTEROLOGY (2004)
Determination of ribavirin in human serum and plasma by capillary electrophoresis
MC Breadmore et al.
ELECTROPHORESIS (2004)
Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection
A Tsubota et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Pharmacokinetics and metabolism of [14C]ribavirin in rats and cynomolgus monkeys
CC Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
S Crotty et al.
NATURE MEDICINE (2000)
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage
L De Franceschi et al.
HEPATOLOGY (2000)
分享论文
